SAGE - Sage upgraded to outperform at RBC on greater confidence in zuranolone approval

2023-03-13 10:58:31 ET

• RBC Capital Markets upgraded Sage Therapeutics ( NASDAQ: SAGE ) to outperform from underperform as it sees a stronger likelihood that depression candidate zuranolone will win approval from the US FDA.
• The firm also upped its price target to $60 from $40 (~52% upside based on Friday's close).
• Analyst Brian Abrahams said the recent announcement that the FDA would not convene at advisory committee meeting for zuranolone bods well for approval. He see a 75% probability of success.
• Also, a survey of physicians RBC conducted found that more are warming up to the drug, which is being developed with Biogen ( BIIB ), given its fast-acting mechanism of action.
• The latest survey found that 25% of them would try zuranolone in its first year, up from 19% in an earlier survey.
• RBC now sees peak sales of $1.9B for depression and $200M for postpartum depression.
• Read why Seeking Alpha contributor William Meyers rates Sage ( SAGE ) a buy.

For further details see: